Screener
Core Laboratories CLB Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 10.3%-0.2pp | 10.7%-0.5pp | 10.6%-0.7pp | 10.4%-0.1pp | 10.5%-0.6pp | |
| Net margin | 5.5%+0.1pp | 5.6%-0.4pp | 6.2%+1.2pp | 5.7%+1.1pp | 5.4%-1.9pp | |
| Returns | ||||||
| Return on equity | 11.1%-0.4pp | 11.6%-1.7pp | 12.3%+1.3pp | 11.8%+1.4pp | 11.5%— | |
| Return on invested capital | 9%+0.3pp | 9.2%-0.6pp | 9.7%+1.5pp | 9.1%+1.5pp | 8.7%— | |
| Efficiency | ||||||
| Asset turnover | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | |
| Liquidity | ||||||
| Current ratio | 2×-0.2× | 2×-0.1× | 2.4×-0.1× | 2.3×-0.1× | 2.2×-0.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.6×-0.1× | 0.6×-0.1× | 0.6×-0.2× | 0.7×-0.2× | 0.7×-0.2× | |
| Net debt / EBITDA | 2.1×-0.2× | 2×-0.2× | 2×-0.3× | 2.2×-0.5× | 2.3×-0.4× | |
| Valuation | ||||||
| Market capitalization | $520.79M+22.8% | $746.41M-8.2% | $579.61M-33.3% | $543.84M-42.6% | $701.93M-11.9% | |
| Price / earnings | 17.9×+3.6× | 25.2×-0.7× | 18×-15.1× | 18.4×-21.6× | 25×+3.8× | |
| Price / sales | 1×+0.2× | 1.4×-0.1× | 1.1×-0.5× | 1.1×-0.8× | 1.4×-0.2× | |
| Price / book | 2.1×+0.3× | 2.8×-0.5× | 2.1×-1.3× | 2.1×-1.9× | 2.8×-0.7× | |
| EV / EBITDA | 10.3×+1.5× | 12.5×-0.8× | 10.4×-3.7× | 10.1×-6.2× | 12.4×-1.3× | |
| Dividend yield | 0.3%-0.1pp | 0.3%0.0pp | 0.3%+0.1pp | 0.3%+0.1pp | 0.3%0.0pp |
FAQ
- Where do Core Laboratories's ratios come from?
- Every ratio is computed from Core Laboratories's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
